
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4AECC8AF310A305AECC0043CFCF20.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="scirep">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368105/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Scientific Reports">
<meta name="citation_title" content="Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes">
<meta name="citation_author" content="Meng Zhang">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China">
<meta name="citation_author" content="Lan Wang">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China">
<meta name="citation_author" content="Qi Wang">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China">
<meta name="citation_author" content="Tian-Hui Guo">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China">
<meta name="citation_author" content="Wen Gao">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China">
<meta name="citation_author" content="Bi-Yuan Zhang">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Laoshan District, Qingdao, 266000 Shandong Province China">
<meta name="citation_author" content="Hai-Ji Wang">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China">
<meta name="citation_author_institution" content="Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Laoshan District, Qingdao, 266000 Shandong Province China">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="15">
<meta name="citation_firstpage" content="30650">
<meta name="citation_doi" content="10.1038/s41598-025-15056-y">
<meta name="citation_pmid" content="40836051">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368105/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368105/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368105/pdf/41598_2025_Article_15056.pdf">
<meta name="description" content="Non-small cell lung cancer (NSCLC) with EGFR mutations presents a unique challenge due to the development of oligometastasis during treatment with first-line tyrosine kinase inhibitors (TKIs). The optimal timing of radiotherapy in EGFR-mutant ...">
<meta name="og:title" content="Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Non-small cell lung cancer (NSCLC) with EGFR mutations presents a unique challenge due to the development of oligometastasis during treatment with first-line tyrosine kinase inhibitors (TKIs). The optimal timing of radiotherapy in EGFR-mutant ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368105/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12368105">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1038/s41598-025-15056-y"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/41598_2025_Article_15056.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12368105%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12368105/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12368105/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368105/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-scirep.jpg" alt="Scientific Reports logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Scientific Reports" title="Link to Scientific Reports" shape="default" href="http://www.nature.com/srep" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Sci Rep</button></div>. 2025 Aug 20;15:30650. doi: <a href="https://doi.org/10.1038/s41598-025-15056-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1038/s41598-025-15056-y</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sci%20Rep%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Sci%20Rep%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Sci%20Rep%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Meng Zhang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Meng Zhang</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Meng Zhang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Lan Wang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Lan Wang</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lan Wang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Qi Wang</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Qi Wang</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qi Wang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guo%20TH%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Tian-Hui Guo</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Tian-Hui Guo</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Guo%20TH%22%5BAuthor%5D" class="usa-link"><span class="name western">Tian-Hui Guo</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Wen Gao</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Wen Gao</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gao%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wen Gao</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20BY%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Bi-Yuan Zhang</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Bi-Yuan Zhang</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China </div>
<div class="p">
<sup>2</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Laoshan District, Qingdao, 266000 Shandong Province China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20BY%22%5BAuthor%5D" class="usa-link"><span class="name western">Bi-Yuan Zhang</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20HJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Hai-Ji Wang</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Hai-Ji Wang</span></h3>
<div class="p">
<sup>1</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China </div>
<div class="p">
<sup>2</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Laoshan District, Qingdao, 266000 Shandong Province China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20HJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Hai-Ji Wang</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, 266000 Shandong Province China </div>
<div id="Aff2">
<sup>2</sup>Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, No. 59 Haier Road, Laoshan District, Qingdao, 266000 Shandong Province China </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 12; Accepted 2025 Aug 5; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12368105  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40836051/" class="usa-link">40836051</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<p id="Par4">Non-small cell lung cancer (NSCLC) with EGFR mutations presents a unique challenge due to the development of oligometastasis during treatment with first-line tyrosine kinase inhibitors (TKIs). The optimal timing of radiotherapy in EGFR-mutant oligometastatic NSCLC remains debated. This study aims to investigate the timing of radiotherapy in relation to disease progression to optimize treatment outcomes. We conducted a retrospective analysis of stage IIIB-IV EGFR-mutant NSCLC patients who received first-line TKI therapy and developed oligoprogressive disease between January 2019 and October 2024. Two groups were compared: one receiving radiotherapy before disease progression (<em>n</em> = 41) and the other post-progression (<em>n</em> = 26). The primary outcomes were progression-free survival (PFS1), progression-free survival after radiotherapy (RT-PFS), and the duration of first-line TKI therapy. Statistical analyses were performed using Kaplan-Meier curves and Cox regression. A total of 67 patients were included. The median PFS1 was 13.8 months in the upfront consolidative radiotherapy group versus 9.8 months in the post-progression group (<em>P</em> = 0.391). The median duration of first-line TKI therapy was significantly longer in the post-progression radiotherapy group (20.3 months vs. 13.3 months, <em>P</em> &lt; 0.001). Kaplan-Meier survival analysis showed a significant difference in TKI duration, suggesting delayed radiotherapy improved TKI duration. This retrospective study suggests that the timing of radiotherapy may influence the duration of first-line EGFR-TKI therapy in patients with oligometastatic NSCLC. Administering local therapy at the time of oligoprogression may help prolong TKI benefit without premature treatment escalation. However, given the study’s retrospective design and potential baseline imbalances, these findings should be interpreted with caution and require validation in future prospective trials.</p>
<section id="sec1"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1038/s41598-025-15056-y.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> EGFR-mutant NSCLC, Oligometastatic disease, Radiotherapy, Tyrosine kinase inhibitors (TKIs)</p></section><section id="kwd-group2" class="kwd-group"><p><strong>Subject terms:</strong> Oncology, Cancer, Medical research, Outcomes research</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par16">Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related morbidity and mortality worldwide<sup><a href="#CR1" class="usa-link" aria-describedby="CR1">1</a></sup>. Oncogene-addicted NSCLC, particularly tumors harboring Epidermal growth factor receptor (EGFR) or (Anaplastic Lymphoma Kinase) ALK alterations, represents a distinct clinical and molecular subtype characterized by strong dependence on specific signaling pathways. Patients with these mutations often respond well to tyrosine kinase inhibitors (TKIs), which have become the standard first-line treatment<sup><a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>,<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a></sup>. However, despite initial treatment responses, disease progression remains a significant challenge, with many patients developing metastases. Oligometastasis, a condition where cancer has spread to a limited number of sites, has been recognized as an intermediate state between localized and widespread metastatic disease<sup><a href="#CR4" class="usa-link" aria-describedby="CR4">4</a></sup>.</p>
<p id="Par17">Recent advances in understanding oligometastatic disease have opened new avenues for treatment, with local therapies, including radiotherapy, emerging as potential strategies to control metastatic sites while preserving the efficacy of systemic treatments<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>–<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a></sup>. Initially, local therapies in oligometastatic NSCLC were predominantly applied after disease progression, targeting oligoprogressive lesions<sup><a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>,<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a></sup>.And with the recognition of residual disease and the emergence of the concept of local consolidative therapy (LCT), there has been a paradigm shift towards earlier integration of local treatments<sup><a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>,<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a></sup>. However, the optimal timing of radiotherapy (RT)-whether before or after progression-remains unclear, especially in the context of EGFR-mutant NSCLC patients receiving first-line TKI therapy.</p>
<p id="Par18">In this retrospective study, we aim to compare the outcomes of two different radiotherapy timing strategies in EGFR-mutant NSCLC patients with oligometastatic disease. By investigating the optimal timing of radiotherapy in the management of oligometastatic EGFR-mutant NSCLC, we hope to provide valuable insights that could inform treatment strategies and improve clinical outcomes in this specific cohort.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Patient characteristics</h3>
<p id="Par19">A total of 67 patients with or without oligometastatic (≤ 5 metastases and ≤ 3organs) NSCLC harboring the EGFR sensitizing mutation and treated with first line TKIs was enrolled between 2019 January to 2024 October (Fig. <a href="#Fig1" class="usa-link">1</a>). Patients were divided into two groups based on the timing of radiotherapy intervention: upfront consolidative radiotherapy (<em>n</em> = 41) and post-progression radiotherapy (<em>n</em> = 26). Baseline characteristics for the entire cohort as well as for the two subgroups are summarized in Tables <a href="#Tab1" class="usa-link">1</a> and <a href="#Tab2" class="usa-link">2</a>.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12368105_41598_2025_15056_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22e7/12368105/c019f8445982/41598_2025_15056_Fig1_HTML.jpg" loading="lazy" id="d33e347" height="1181" width="781" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flowchart showing selection process for patients. EGFR, Epidermal Growth Factor Receptor; TKIs, Tyrosine Kinase Inhibitors.</p></figcaption></figure><section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Patient characteristics of entire cohort.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Characteristics</th>
<th align="left" colspan="1" rowspan="1">
<em>N</em>
</th>
<th align="left" colspan="1" rowspan="1">No. of patients (%)</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="3" rowspan="1">Age (59.1,31–78)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt;60</td>
<td align="left" colspan="1" rowspan="1">35</td>
<td align="left" colspan="1" rowspan="1">52.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 60</td>
<td align="left" colspan="1" rowspan="1">32</td>
<td align="left" colspan="1" rowspan="1">47.8</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Gender</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male</td>
<td align="left" colspan="1" rowspan="1">31</td>
<td align="left" colspan="1" rowspan="1">46.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="left" colspan="1" rowspan="1">36</td>
<td align="left" colspan="1" rowspan="1">53.7</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">ECOG status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0–1</td>
<td align="left" colspan="1" rowspan="1">63</td>
<td align="left" colspan="1" rowspan="1">94</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Histology</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1">67</td>
<td align="left" colspan="1" rowspan="1">100</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">EGFR mutation</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Exon19 deletion</td>
<td align="left" colspan="1" rowspan="1">26</td>
<td align="left" colspan="1" rowspan="1">38.8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Exon 21 L858R</td>
<td align="left" colspan="1" rowspan="1">32</td>
<td align="left" colspan="1" rowspan="1">47.8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Exon 18</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">7.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Exon 20</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Smoking status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">28</td>
<td align="left" colspan="1" rowspan="1">41.8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">39</td>
<td align="left" colspan="1" rowspan="1">58.2</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">T stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">1–2</td>
<td align="left" colspan="1" rowspan="1">37</td>
<td align="left" colspan="1" rowspan="1">55.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3–4</td>
<td align="left" colspan="1" rowspan="1">30</td>
<td align="left" colspan="1" rowspan="1">44.8</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">N stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0–1</td>
<td align="left" colspan="1" rowspan="1">8</td>
<td align="left" colspan="1" rowspan="1">11.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2–3</td>
<td align="left" colspan="1" rowspan="1">59</td>
<td align="left" colspan="1" rowspan="1">88.1</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">M stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">46</td>
<td align="left" colspan="1" rowspan="1">68.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">21</td>
<td align="left" colspan="1" rowspan="1">31.3</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">No. of metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">21</td>
<td align="left" colspan="1" rowspan="1">31.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">1–2</td>
<td align="left" colspan="1" rowspan="1">27</td>
<td align="left" colspan="1" rowspan="1">40.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3–5</td>
<td align="left" colspan="1" rowspan="1">19</td>
<td align="left" colspan="1" rowspan="1">28.4</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Metastasis location</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Brain</td>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">23.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bone</td>
<td align="left" colspan="1" rowspan="1">21</td>
<td align="left" colspan="1" rowspan="1">31.3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Adrenal</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Liver</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">4.5</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pleura</td>
<td align="left" colspan="1" rowspan="1">8</td>
<td align="left" colspan="1" rowspan="1">11.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No-regional lymph nodes</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">7.5</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Radiotherapy site</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lung</td>
<td align="left" colspan="1" rowspan="1">49</td>
<td align="left" colspan="1" rowspan="1">74.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bone</td>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">15.2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Brain</td>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">15.2</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">TRP</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">1–2 grades</td>
<td align="left" colspan="1" rowspan="1">4</td>
<td align="left" colspan="1" rowspan="1">6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 3 grades</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">1.5</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">TKI drugs</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">First generation</td>
<td align="left" colspan="1" rowspan="1">38</td>
<td align="left" colspan="1" rowspan="1">56.7</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Second generation</td>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">17.9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Third generation</td>
<td align="left" colspan="1" rowspan="1">17</td>
<td align="left" colspan="1" rowspan="1">25.4</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Initial chemotherapy</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">32</td>
<td align="left" colspan="1" rowspan="1">47.8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">35</td>
<td align="left" colspan="1" rowspan="1">52.2</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Definitive or Palliative chemotherapy</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Definitive</td>
<td align="left" colspan="1" rowspan="1">11</td>
<td align="left" colspan="1" rowspan="1">16.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Palliative</td>
<td align="left" colspan="1" rowspan="1">21</td>
<td align="left" colspan="1" rowspan="1">31.3</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Patterns of progression</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Local progression</td>
<td align="left" colspan="1" rowspan="1">52</td>
<td align="left" colspan="1" rowspan="1">77.60%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Distant metastasis</td>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">17.90%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Progress of distant metastases</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">4.50%</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Patient characteristics of two groups.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Characteristics</th>
<th align="left" colspan="1" rowspan="1">Post-progression RT (<em>n</em> = 26)</th>
<th align="left" colspan="1" rowspan="1">Upfront consolidative RT (<em>n</em> = 41)</th>
<th align="left" rowspan="2" colspan="1">
<em>P</em> value</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">No. (%)</th>
<th align="left" colspan="1" rowspan="1">No. (%)</th>
</tr>
</thead>
<tbody>
<tr><td align="left" colspan="4" rowspan="1">Age</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt;60</td>
<td align="left" colspan="1" rowspan="1">11(42.3)</td>
<td align="left" colspan="1" rowspan="1">24(58.8)</td>
<td align="left" colspan="1" rowspan="1">0.219</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 60</td>
<td align="left" colspan="1" rowspan="1">15(57.7)</td>
<td align="left" colspan="1" rowspan="1">17(41.5)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Gender</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male</td>
<td align="left" colspan="1" rowspan="1">11(42.3)</td>
<td align="left" colspan="1" rowspan="1">20(48.8)</td>
<td align="left" colspan="1" rowspan="1">0.626</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Female</td>
<td align="left" colspan="1" rowspan="1">15(57.7)</td>
<td align="left" colspan="1" rowspan="1">21(51.2)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">ECOG status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0–1</td>
<td align="left" colspan="1" rowspan="1">25(96.2)</td>
<td align="left" colspan="1" rowspan="1">38(92.7)</td>
<td align="left" colspan="1" rowspan="1">0.652</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1(3.8)</td>
<td align="left" colspan="1" rowspan="1">3(7.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Histology</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1">26(100)</td>
<td align="left" colspan="1" rowspan="1">41(100)</td>
<td align="left" colspan="1" rowspan="1">-</td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">EGFR mutation</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Exon19 deletion</td>
<td align="left" colspan="1" rowspan="1">9(34.6)</td>
<td align="left" colspan="1" rowspan="1">17(41.5)</td>
<td align="left" colspan="1" rowspan="1">0.436</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Exon 21 L858R</td>
<td align="left" colspan="1" rowspan="1">13(50)</td>
<td align="left" colspan="1" rowspan="1">19(46.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Exon 18</td>
<td align="left" colspan="1" rowspan="1">1(3.8)</td>
<td align="left" colspan="1" rowspan="1">4(9.8)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Exon 20</td>
<td align="left" colspan="1" rowspan="1">3(11.5)</td>
<td align="left" colspan="1" rowspan="1">1(2.4)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Smoking status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">12(46.2)</td>
<td align="left" colspan="1" rowspan="1">16(39)</td>
<td align="left" colspan="1" rowspan="1">0.617</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">14(53.8)</td>
<td align="left" colspan="1" rowspan="1">25(61)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">T stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">1–2</td>
<td align="left" colspan="1" rowspan="1">17(65.4)</td>
<td align="left" colspan="1" rowspan="1">20(48.8)</td>
<td align="left" colspan="1" rowspan="1">0.215</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3–4</td>
<td align="left" colspan="1" rowspan="1">9(34.6)</td>
<td align="left" colspan="1" rowspan="1">21(51.2)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">N stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0–1</td>
<td align="left" colspan="1" rowspan="1">3(11.5)</td>
<td align="left" colspan="1" rowspan="1">5(12.2)</td>
<td align="left" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">2–3</td>
<td align="left" colspan="1" rowspan="1">23(88.5)</td>
<td align="left" colspan="1" rowspan="1">36(87.8)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">M stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">7(26.9)</td>
<td align="left" colspan="1" rowspan="1">14(34.1)</td>
<td align="left" colspan="1" rowspan="1">0.598</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">19(73.1)</td>
<td align="left" colspan="1" rowspan="1">27(65.9)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">No. of metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">7(26.9)</td>
<td align="left" colspan="1" rowspan="1">14(34.1)</td>
<td align="left" colspan="1" rowspan="1">0.856</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">1–2</td>
<td align="left" colspan="1" rowspan="1">11(42.3)</td>
<td align="left" colspan="1" rowspan="1">16(39)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">3–5</td>
<td align="left" colspan="1" rowspan="1">8(30.8)</td>
<td align="left" colspan="1" rowspan="1">11(26.8)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Metastasis location</td></tr>
<tr><td align="left" colspan="4" rowspan="1">Brain</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">22(84.6)</td>
<td align="left" colspan="1" rowspan="1">29(70.7)</td>
<td align="left" colspan="1" rowspan="1">0.247</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">4(15.4)</td>
<td align="left" colspan="1" rowspan="1">12(29.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Bone</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">17(65.4)</td>
<td align="left" colspan="1" rowspan="1">29(70.7)</td>
<td align="left" colspan="1" rowspan="1">0.788</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">yes</td>
<td align="left" colspan="1" rowspan="1">9(34.6)</td>
<td align="left" colspan="1" rowspan="1">12(29.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Adrenal</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">24(92.3)</td>
<td align="left" colspan="1" rowspan="1">39(95.1)</td>
<td align="left" colspan="1" rowspan="1">0.638</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">2(7.7)</td>
<td align="left" colspan="1" rowspan="1">2(4.9)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Liver</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">26(100)</td>
<td align="left" colspan="1" rowspan="1">38(92.7)</td>
<td align="left" colspan="1" rowspan="1">0.277</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">3(7.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Pleura</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">21(80.8)</td>
<td align="left" colspan="1" rowspan="1">38(92.7)</td>
<td align="left" colspan="1" rowspan="1">0.245</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">5(19.2)</td>
<td align="left" colspan="1" rowspan="1">3(7.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">No-regional lymph nodes</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">23(88.5)</td>
<td align="left" colspan="1" rowspan="1">39(95.1)</td>
<td align="left" colspan="1" rowspan="1">0.369</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">3(11.5)</td>
<td align="left" colspan="1" rowspan="1">2(4.9)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Radiotherapy site</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lung</td>
<td align="left" colspan="1" rowspan="1">21(84)</td>
<td align="left" colspan="1" rowspan="1">28(68.3)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bone</td>
<td align="left" colspan="1" rowspan="1">3(12)</td>
<td align="left" colspan="1" rowspan="1">6(14.3)</td>
<td align="left" colspan="1" rowspan="1">0.525</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Brain</td>
<td align="left" colspan="1" rowspan="1">2(8)</td>
<td align="left" colspan="1" rowspan="1">7(17.1)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">TRP</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">1–2 grades</td>
<td align="left" colspan="1" rowspan="1">1(4.7%)</td>
<td align="left" colspan="1" rowspan="1">3(6.5%)</td>
<td align="left" colspan="1" rowspan="1">0.758</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">≥ 3 grades</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">1(2.4%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">TKI drugs</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">First generation</td>
<td align="left" colspan="1" rowspan="1">14(53.8)</td>
<td align="left" colspan="1" rowspan="1">24(58.5)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Second generation</td>
<td align="left" colspan="1" rowspan="1">5(19.2)</td>
<td align="left" colspan="1" rowspan="1">7(17.1)</td>
<td align="left" colspan="1" rowspan="1">0.944</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Third generation</td>
<td align="left" colspan="1" rowspan="1">7(26.9)</td>
<td align="left" colspan="1" rowspan="1">10(24.4)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Initial chemotherapy</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No</td>
<td align="left" colspan="1" rowspan="1">17(65.4)</td>
<td align="left" colspan="1" rowspan="1">8(43.9)</td>
<td align="left" colspan="1" rowspan="1">0.132</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yes</td>
<td align="left" colspan="1" rowspan="1">9(34.6)</td>
<td align="left" colspan="1" rowspan="1">23(56.1)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Definitive or Palliative chemotherapy</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Definitive</td>
<td align="left" colspan="1" rowspan="1">2(22.2%)</td>
<td align="left" colspan="1" rowspan="1">9(39.1%)</td>
<td align="left" colspan="1" rowspan="1">0.441</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Palliative</td>
<td align="left" colspan="1" rowspan="1">7(77.8%)</td>
<td align="left" colspan="1" rowspan="1">14(60.9%)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="4" rowspan="1">Patterns of progression</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Local progression</td>
<td align="left" colspan="1" rowspan="1">20(76.9)</td>
<td align="left" colspan="1" rowspan="1">32(78.0)</td>
<td align="left" colspan="1" rowspan="1">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Distant metastasis</td>
<td align="left" colspan="1" rowspan="1">5(19.2)</td>
<td align="left" colspan="1" rowspan="1">7(17.1)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Progress of distant metastases</td>
<td align="left" colspan="1" rowspan="1">1(3.8)</td>
<td align="left" colspan="1" rowspan="1">2(4.9)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section id="Sec4"><h4 class="pmc_sec_title">General patient characteristics</h4>
<p id="Par23">The median age was 59.1 years (range, 31–78), with 52.2% (<em>n</em> = 35) of patients aged &lt; 60 years. All patients had adenocarcinoma histology, with EGFR mutations identified as follows: 38.8%(<em>n</em> = 26) exon 19 deletion, 47.8%(<em>n</em> = 32) exon 21 L858R, 7.5%(<em>n</em> = 5) exon 18, and 6%(<em>n</em> = 4) exon 20 mutations. The majority of patients had an ECOG performance status of 0–1 (94%, <em>n</em> = 63), with only 6% having a status of 2.</p>
<p id="Par24">Regarding clinical features, most patients presented with T1-2 tumors (55.2%, <em>n</em> = 37) and N2-3 disease (88.1%, <em>n</em> = 59). A substantial proportion (68.7%, <em>n</em> = 46) had distant metastases (M1). Common metastatic sites included bone (31.3%, <em>n</em> = 21), brain (23.9%, <em>n</em> = 16), and pleura (11.9%, <em>n</em> = 8). Radiotherapy was primarily administered to the lung (74.2%, <em>n</em> = 49), followed by bone and brain.</p>
<p id="Par25">In terms of treatment, 56.7% of patients received first-generation EGFR-TKIs, with the remainder receiving second- or third-generation TKIs. Half of the patients (47.8%, <em>n</em> = 35) underwent initial chemotherapy. Disease progression patterns were predominantly local (77.6%, <em>n</em> = 52), with fewer patients experiencing distant metastasis (17.9%, <em>n</em> = 12). The TRP rate is 7.5%. All characteristics are listed in Table <a href="#Tab1" class="usa-link">1</a>.</p></section><section id="Sec5"><h4 class="pmc_sec_title">Radiotherapy parameters of patients</h4>
<p id="Par26">A total of 67 patients received radiotherapy targeting lung, brain, or bone lesions, with detailed radiotherapy parameters summarized in <strong>Table </strong><a href="#MOESM1" class="usa-link"><strong>S1</strong></a>.</p>
<p id="Par27">Lung was the most commonly irradiated site, with 49 patients (73.1%) receiving thoracic radiotherapy. Among them, 45 patients (26.9%) received conventional radiotherapy (56–66 Gy in 28–33 fractions), and 4 (6%) patients received stereotactic body radiotherapy (SBRT) to lung lesions (50–60 Gy in 3–8 fractions).</p>
<p id="Par28">Brain radiotherapy was administered to 9 patients (13.4%) using SBRT (45–50 Gy in 10 fractions), all with palliative intent.</p>
<p id="Par29">Bone radiotherapy was performed in 9 patients (13.4%), including 5 patients treated with 30 Gy in 10 fractions and 4 patients receiving higher-dose regimens (40–50 Gy in 20–25 fractions), all with palliative intent.</p></section><section id="Sec6"><h4 class="pmc_sec_title">Comparison between Pre- and Post-Progression radiotherapy groups</h4>
<p id="Par30">The baseline characteristics of patients in the upfront consolidative and post-progression radiotherapy groups were comparable, with no significant differences in key clinical variables, including age, gender, ECOG performance status, smoking history, EGFR mutation status, tumor staging (T, N, M stages), metastatic sites, radiotherapy sites, and prior chemotherapy use. Specifically, the distribution of EGFR mutations, including exon 19 deletions and exon 21 L858R mutations, was similar between the groups. Both groups also exhibited comparable tumor burden, with similar proportions of patients having T1-2 and N2-3 disease, as well as similar metastatic patterns. In particular, it should be noted that TRP were comparable between the two groups. Grade 1–2 TRP occurred in one patient (4.7%) in post-progression Group and three patients (6.5%) in upfront consolidative group. Grade ≥ 3 TRP occurred in no patients in post-progression Group and one patient (2.2%) in upfront consolidative group. These findings suggest that the baseline characteristics of the two groups were well-balanced, supporting the assumption that any observed differences in the duration of first-line TKI therapy can be attributed primarily to the timing of radiotherapy intervention, rather than other confounding factors. All characteristics are listed in Table <a href="#Tab2" class="usa-link">2</a>.</p></section></section><section id="Sec7"><h3 class="pmc_sec_title">Survival outcomes</h3>
<p id="Par31">Median follow-up time was 15.1 months. For the entire cohort, the median PFS1 was 11.7 months. It was 13.8 months (95% CI: 10.15–17.51) in the upfront consolidative radiotherapy group and 9.8 months (95% CI: 5.47–14.13) in the post-progression radiotherapy group (<em>P</em> = 0.391). And the median PFS2 in the post-progression radiotherapy group was 8.5months, we also analyzed the RT-PFS between the two groups and found no statistically significant difference (8.0 months, 95% CI: 6.37-9.63vs. 5.7 months, 95% CI:4.17–7.17, <em>P</em> = 0.122).</p>
<p id="Par32">There was a statistically significant difference in the duration of first-line EGFR-TKI therapy between the two groups. Patients in the post-progression RT group had a longer TKI duration compared to the upfront consolidative RT group (median 20.3 vs. 13.3 months; <em>p</em> &lt; 0.001, log-rank test), as shown by Kaplan–Meier analysis. These results suggest that the timing of RT intervention has a significant impact on the duration of first-line TKI therapy, delaying RT intervention associated with prolonged TKI duration (Fig. <a href="#Fig2" class="usa-link">2</a>).</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12368105_41598_2025_15056_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22e7/12368105/44ef47d59d8b/41598_2025_15056_Fig2_HTML.jpg" loading="lazy" id="d33e1380" height="525" width="669" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>(<strong>A</strong>) PFS1, (<strong>B</strong>) days from RT and (<strong>C</strong>) duration of first-line TKI of patients treated in Pre- and Post-Progression Radiotherapy Groups.</p></figcaption></figure><p id="Par34">To further explore whether the effect of radiotherapy timing varied by treatment site, subgroup analyses were conducted according to irradiated sites, including lung, brain, and bone. As shown in Figure <a href="#MOESM1" class="usa-link">S1</a>, TKI duration was significantly longer and statistically significant for lung radiotherapy in Figure <a href="#MOESM1" class="usa-link">S1</a>(B), and a similar trend was observed in Figure <a href="#MOESM1" class="usa-link">S1</a>(A), although not statistically significant.</p></section><section id="Sec8"><h3 class="pmc_sec_title">Univariate and multivariate analyses of the duration of first-line TKI therapy</h3>
<p id="Par35">Univariable Cox regression analysis revealed that factors significantly associated with prolonged TKI duration included primary tumor (HR = 0.46, 95% CI: 0.26–0.81, <em>P</em> = 0.008), lower T stage (T1-2 vs. T3-4, HR = 2.09, 95% CI: 1.24–3.54, <em>P</em> = 0.006) and first generation TKI (1 vs. 2, HR = 2.16, CI: 1.09–4.26, <em>P</em> <strong>=</strong> 0.027). In multivariable Cox regression analysis, primary tumor (HR = 0.39, 95% CI: 0.21–0.71, <em>P</em> = 0.002) and lower T stage (HR = 2.53, 95% CI: 1.40–4.59, <em>P</em> = 0.002) were independently associated with prolonged TKI duration (Table <a href="#Tab3" class="usa-link">3</a>). These findings indicate that primary tumor, lower T stage, and initial chemotherapy are critical predictors of longer TKI treatment duration.</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Univariate and multivariate analyses of the duration of first-line TKI therapy.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Variable</th>
<th align="left" colspan="3" rowspan="1">Univariable</th>
<th align="left" colspan="3" rowspan="1">Multivariable</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1">HR</th>
<th align="left" colspan="1" rowspan="1">95%CI</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>
</th>
<th align="left" colspan="1" rowspan="1">HR</th>
<th align="left" colspan="1" rowspan="1">95%</th>
<th align="left" colspan="1" rowspan="1">
<em>P</em>
</th>
</tr>
</thead>
<tbody>
<tr><td align="left" colspan="7" rowspan="1">Age</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">&lt; 60 vs. ≥60</td>
<td align="left" colspan="1" rowspan="1">1.13</td>
<td align="left" colspan="1" rowspan="1">0.69–1.85</td>
<td align="left" colspan="1" rowspan="1">0.619</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Gender</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Male vs. female</td>
<td align="left" colspan="1" rowspan="1">0.71</td>
<td align="left" colspan="1" rowspan="1">0.43–1.15</td>
<td align="left" colspan="1" rowspan="1">0.161</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">ECOG</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0–1 vs. 2</td>
<td align="left" colspan="1" rowspan="1">1.66</td>
<td align="left" colspan="1" rowspan="1">0.60–4.60</td>
<td align="left" colspan="1" rowspan="1">0.33</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">EGFR mutation</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">EGFR 19del vs. 21L858R</td>
<td align="left" colspan="1" rowspan="1">0.79</td>
<td align="left" colspan="1" rowspan="1">0.47–1.34</td>
<td align="left" colspan="1" rowspan="1">0.386</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EGFR 18 exon vs. 21L858R</td>
<td align="left" colspan="1" rowspan="1">2.35</td>
<td align="left" colspan="1" rowspan="1">0.89–6.19</td>
<td align="left" colspan="1" rowspan="1">0.083</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">EGFR 20 exon vs. 21L858R</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">0.35–2.85</td>
<td align="left" colspan="1" rowspan="1">0.998</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Smoking status</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No vs. Yes</td>
<td align="left" colspan="1" rowspan="1">0.97</td>
<td align="left" colspan="1" rowspan="1">0.59–1.59</td>
<td align="left" colspan="1" rowspan="1">0.911</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">T stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">1–2 vs. 3–4</td>
<td align="left" colspan="1" rowspan="1">2.09</td>
<td align="left" colspan="1" rowspan="1">1.24–3.54</td>
<td align="left" colspan="1" rowspan="1">
<strong>0.01</strong>
</td>
<td align="left" colspan="1" rowspan="1">2.5</td>
<td align="left" colspan="1" rowspan="1">1.40–4.59</td>
<td align="left" colspan="1" rowspan="1">
<strong>0</strong>
</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">N stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">0–1 vs. 2–3</td>
<td align="left" colspan="1" rowspan="1">0.78</td>
<td align="left" colspan="1" rowspan="1">0.37–1.65</td>
<td align="left" colspan="1" rowspan="1">0.517</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">M stage</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No vs. Yes</td>
<td align="left" colspan="1" rowspan="1">0.74</td>
<td align="left" colspan="1" rowspan="1">0.43–1.27</td>
<td align="left" colspan="1" rowspan="1">0.278</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Metastasis location</td></tr>
<tr><td align="left" colspan="7" rowspan="1">Brain metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No vs. Yes</td>
<td align="left" colspan="1" rowspan="1">1.3</td>
<td align="left" colspan="1" rowspan="1">0.73–2.30</td>
<td align="left" colspan="1" rowspan="1">0.369</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Lung Radiation</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No vs. Yes</td>
<td align="left" colspan="1" rowspan="1">0.46</td>
<td align="left" colspan="1" rowspan="1">0.26–0.81</td>
<td align="left" colspan="1" rowspan="1">
<strong>0.01</strong>
</td>
<td align="left" colspan="1" rowspan="1">0.4</td>
<td align="left" colspan="1" rowspan="1">0.21–0.71</td>
<td align="left" colspan="1" rowspan="1">
<strong>0</strong>
</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">TKI drugs</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">1 vs. 2</td>
<td align="left" colspan="1" rowspan="1">2.16</td>
<td align="left" colspan="1" rowspan="1">1.09–4.26</td>
<td align="left" colspan="1" rowspan="1">
<strong>0.03</strong>
</td>
<td align="left" colspan="1" rowspan="1">1.1</td>
<td align="left" colspan="1" rowspan="1">0.50–2.23</td>
<td align="left" colspan="1" rowspan="1">0.88</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">1 vs. 3</td>
<td align="left" colspan="1" rowspan="1">1.07</td>
<td align="left" colspan="1" rowspan="1">0.59–1.93</td>
<td align="left" colspan="1" rowspan="1">0.83</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">0.57–1.84</td>
<td align="left" colspan="1" rowspan="1">0.95</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Initial chemotherapy</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">No vs. Yes</td>
<td align="left" colspan="1" rowspan="1">0.91</td>
<td align="left" colspan="1" rowspan="1">0.55–1.48</td>
<td align="left" colspan="1" rowspan="1">0.695</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Patterns of progression</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Local vs. Distant</td>
<td align="left" colspan="1" rowspan="1">1.08</td>
<td align="left" colspan="1" rowspan="1">0.60–1.93</td>
<td align="left" colspan="1" rowspan="1">0.8</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section></section><section id="Sec9"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par37">The management paradox in EGFR-mutant oligometastatic NSCLC lies in balancing the potential benefits of early local control against preserving systemic therapy efficacy. In this context, several studies have explored the progression patterns of oligometastatic disease in EGFR-mutant NSCLC. Al-Halabi et al.<sup><a href="#CR11" class="usa-link" aria-describedby="CR11">11</a></sup> conducted a retrospective analysis of 49 EGFR-mutant metastatic NSCLC patients treated with TKI therapy, finding that lung was the most common site for both metastasis and disease progression, with 45% of patients experiencing progression at the primary site. Yoshida et al.<sup><a href="#CR12" class="usa-link" aria-describedby="CR12">12</a></sup> similarly reported that isolated progression, most commonly in the lung, was associated with prolonged survival after TKI failure. Li et al.<sup><a href="#CR13" class="usa-link" aria-describedby="CR13">13</a></sup> showed that oligometastatic patients often progress as oligoprogression (72.7%), with disease mainly confined to the residual metastatic sites, especially in the lung(60.6%).Another retrospective study of EGFR-mutant NSCLC patients demonstrated similar findings, among the 60 patients with oligoresidual disease, 44 (73%) experienced disease progression confined to the oligoresidual sites<sup><a href="#CR14" class="usa-link" aria-describedby="CR14">14</a></sup>.</p>
<p id="Par38">These findings suggest that in EGFR-positive NSCLC, recurrence predominantly affects the primary tumor site, and oligometastatic EGFR-mutant NSCLC patients are more likely to develop oligoprogression, particularly at the lung primary site. This may indicate a biologically indolent behavior in this subset of patients, raising the question of whether early radiotherapy intervention could be beneficial for controlling progression and prolonging the effectiveness of systemic therapy in this group.</p>
<p id="Par39">Based on this, current ASTRO/ESTRO guidelines recommend definitive local therapy for oligometastatic disease<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a></sup>, landmark trials support this recommendation<sup><a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>–<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a></sup>, but did not differentiate between oligo-progressors and extensively progressed patients. Our study specifically challenges the paradigm in this context of EGFR-driven biology, aiming to investigate the optimal timing of radiotherapy intervention in EGFR-mutant oligometastatic NSCLC patients. According to comparing outcomes between patients receiving radiotherapy during stable disease and after oligoprogression, our findings demonstrate that deferring radiotherapy until oligoprogression extends first-line TKI duration by 7 months (20.3 vs. 13.3 months, P &lt; 0.001), providing a rational for addressing the clinical dilemma of"when to ablate locally” in first-line EGFR-TKI therapy populations.</p>
<p id="Par40">While PFS1 and RT-PFS did not show statistically significant differences between the two groups, these findings provide complementary context to the observed difference in TKI duration. The absence of significant separation in PFS1 may be due to the fact that all patients initially responded to first-line EGFR-TKI, resulting in similar early disease control. In addition, variability in radiotherapy targets and timing may have attenuated differences in RT-PFS. Although PFS1 and RT-PFS are conventional survival metrics, TKI duration reflects real-world treatment continuity and decision-making. Therefore, we believe these endpoints should be interpreted together, with TKI duration offering additional practical insight into the benefit of delayed radiotherapy in this setting.</p>
<p id="Par41">Our cohort analysis revealed three key findings. First, the prolonged TKI usage in the post-progression group (20.3 months, 95% CI: 15.10–25.43 vs. 13.3 months, 95% CI: 9.98–16.65, <em>P</em> &lt; 0.001) suggests that the timing of radiotherapy may influence the evolutionary trajectory of resistant clones, with the potential to extend the duration of effective TKI therapy. This supports an evolutionary model where early ablation of TKI-sensitive clones accelerates selection of resistant populations. Second, several studies suggest that oligometastatic NSCLC often progresses at limited sites without a rapid increase in overall tumor burden<sup><a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>,<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a></sup>. In our study, the median 9.8-month interval (95% CI: 5.47–14.13) to oligoprogression implies that EGFR-mutant tumors may present a “golden window” for delayed intervention, offering a distinct opportunity for treatment strategies in patients with slower progression compared to rapid progressors. Finally, lung-targeted radiotherapy independently predicted longer TKI duration (HR = 0.46, 95% CI: 0.26–0.81, <em>P</em> = 0.008), potentially reflecting better control of primary resistant niches in the lung compared to metastases in other anatomical sites, such as bone or adrenal glands. This is consistent with Sun et al.‘s recent study<sup><a href="#CR21" class="usa-link" aria-describedby="CR21">21</a></sup>, which found that combining thoracic radiotherapy with TKI therapy prolonged PFS and OS (mPFS: 17.1 vs. 10.6 months, <em>P</em> = 0.004; mOS: 34.4 vs. 26.2 months, <em>P</em> = 0.029), with treatment-related adverse events (TRAEs) remaining manageable. These findings further support the potential of consolidative radiotherapy to enhance disease control and prolong the efficacy of targeted therapy. These findings highlight the significance of radiotherapy timing and anatomical specificity in optimizing the management of EGFR-mutant NSCLC.</p>
<p id="Par42">To evaluate the statistical power of our findings, we conducted a post-hoc power analysis. Based on the observed TKI durations and standard deviations between the two groups, with a two-sided significance level of 0.05 and a sample size of 67, the statistical power was calculated to exceed 80%, indicating that our study had sufficient power to detect meaningful differences.</p>
<p id="Par43">However, our study does have several limitations. First, due to the retrospective design and incomplete documentation, TRAEs, particularly radiation-related toxicities, we only counted the incidence of TRP, and did not consider other adverse effects systematically. Although prior meta-analyses have shown a manageable toxicity profile (e.g., 3.8% incidence of TRP)<sup><a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>,<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a></sup>, real-world safety data from our cohort remains lacking. Secondly, the sample size was relatively small, and the non-randomized design may introduce selection bias. Thirdly, the relatively short follow-up period limits our ability to assess long-term survival outcomes such as overall survival (OS).</p>
<p id="Par44">Our results suggest that the timing of radiotherapy should be individualized according to disease dynamics. Initiating treatment with systemic EGFR-TKI therapy during the oligometastatic phase, followed by radiotherapy at the time of oligoprogression, may be an effective strategy to prolong TKI duration. Nevertheless, we acknowledge that the retrospective design, non-randomized group allocation, and baseline imbalances may introduce potential bias. Therefore, our conclusions should be interpreted with caution. Future multicenter, prospective trials with larger sample sizes and longer follow-up are essential to confirm the survival benefit associated with delayed radiotherapy. Furthermore, additional studies are warranted to refine radiotherapy protocols to further improve outcomes in patients with EGFR-mutant oligometastatic NSCLC, including treatment modality, dose, fractionation, and target site selection.</p></section><section id="Sec10"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par45">This study demonstrates that the timing of radiotherapy in patients with EGFR-mutant oligometastatic NSCLC has a significant impact on the duration of first-line EGFR-TKI therapy. Administering radiotherapy after the onset of oligoprogression was associated with a substantially longer duration of TKI treatment compared to early radiotherapy intervention. These findings highlight the potential clinical value of optimizing treatment sequencing to maximize the efficacy of targeted therapies and improve patient outcomes. However, given the retrospective design and limited sample size, these conclusions should be interpreted with caution.</p></section><section id="Sec11"><h2 class="pmc_sec_title">Materials and methods</h2>
<section id="Sec12"><h3 class="pmc_sec_title">Definition of oligometastatic and oligoprogressive disease</h3>
<p id="Par46">In this study, the classification of oligometastatic and oligoprogressive disease was based on the international consensus statement on synchronous NSCLC published in 2019<sup><a href="#CR24" class="usa-link" aria-describedby="CR24">24</a></sup>. Oligometastatic disease was defined as the presence of five or fewer metastatic lesions in up to three organs, all of which were technically amenable to local radical treatment. The definition included intrathoracic metastases, such as contralateral lung nodules, pleural lesions, and chest wall involvement, as long as they were isolated, limited in number, and suitable for local therapy.</p>
<p id="Par47">Oligoprogression was defined as limited progression (≤ 5 new or enlarging lesions) occurring during ongoing EGFR-TKI therapy, with the remainder of the disease remaining controlled. Patients were eligible if the progressive lesions were technically suitable for local treatment, such as radiotherapy or surgery.</p>
<p id="Par48">We explicitly included patients with isolated thoracic progression (e.g., lung, mediastinum, chest wall) under the oligoprogressive category, in accordance with the consensus recommendation that anatomic location alone should not exclude patients from the oligometastatic spectrum if local treatment is feasible.</p></section><section id="Sec13"><h3 class="pmc_sec_title">Acquisition of clinical data</h3>
<p id="Par49">We conducted a retrospective study on stage IIIB-IV EGFR-mutated NSCLC patients who received first-line TKI therapy and developed oligoprogression between January 2019 and October 2024 at the Affiliated Hospital of Qingdao university. This study was approved by the ethics committees of the Affiliated Hospital of Qingdao university, China (Reference No. QYFYWZLL29747). All experiments involving human participants were conducted in accordance with the Declaration of Helsinki and relevant institutional guidelines and regulations. Due to the retrospective nature of this study, the requirement for informed consent was waived by the Ethics Committee of the Affiliated Hospital of Qingdao University. The inclusion criteria were as follows: 1) Pathologically confirmed diagnosis of oligometastatic NSCLC with an activating EGFR mutation (including Exon19 deletion, Exon 21 L858R, Exon 18 and Exon 20 mutation);2) Initial response to first-line TKI therapy, followed by the development of oligoprogression or oligometastatic disease during ongoing TKI treatment. Of note, patients who received chemotherapy were only included if the chemotherapy was administered concurrently with EGFR-TKI as part of the initial treatment regimen. This approach was not considered a prior line of therapy; 3) Patients classified into two groups based on the timing of radiotherapy in relation to disease progression: (a) The post-progression group included patients who developed oligoprogression or oligometastasis during ongoing TKI therapy. Then they received radiotherapy, continuing the same TKI until further progression. (b) The upfront consolidative RT group comprised patients who had received at least 6–8 weeks (deemed effective) of continuous and effective TKI therapy and underwent consolidative radiotherapy before any evidence of disease progression. The same TKI therapy was continued after RT until oligometastases. Disease progression was rigorously defined according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by institutional investigators. All imaging was reviewed by board-certified radiologists, and ambiguous cases were discussed and confirmed in multidisciplinary tumor board (MDT) meetings.4) Age ≥ 18 years; 5) Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2. The exclusion criteria were as follows: (1) Incomplete Imaging Data or Irregular Follow-up; (2) Irregular Medication Use or Arbitrary Change of TKI; (3) With other malignancies or severe comorbidities. Oligoprogression was defined as the presence of ≤ 5 metastatic lesions in ≤ 3 organs. It’s important to note that patient enrollment criteria were determined by the course of the disease, and these patients eventually developed oligometastasis or oligoprogression, regardless of initial TNM staging. Some patients were initially diagnosed with stage IIIB or IIIC (M0), but were included in the study after progression to oligometastasis during EGFR-TKI treatment, at the time of radiotherapy, some patients remained in the locally advanced stage, while others had progressed to oligometastasis. A flowchart summarizing the patient grouping and treatment sequence is presented in Figure S2.</p></section><section id="Sec14"><h3 class="pmc_sec_title">EGFR mutation and radiotherapy</h3>
<p id="Par50">Genomic DNA was extracted from paraffin-embedded specimens obtained by percutaneous needle biopsy or bronchoscopy in patients with accessible lesions. For patients with only cytological samples available, methanol-fixed cytologic specimens from pleural effusions or bronchial lavage fluid were used for DNA extraction. EGFR mutation analysis was performed using the ARMS method or direct sequencing, and the specific mutations, including EGFR exon 19 deletions (19del) and EGFR exon 21 L858R point mutations, were identified.</p>
<p id="Par51">The decision to administer local radiation therapy was made by a multidisciplinary team (including oncologists, radiation oncologists, radiologists, pulmonologists, and other relevant specialists). The radiotherapy plan was developed by taking into account the patient’s overall health, tumor size and location, and other clinical parameters, including organ function.</p>
<p id="Par52">Patients in the upfront consolidative RT group received radiotherapy during ongoing first-line EGFR-TKI therapy before any radiographic evidence of progression. In these cases, oligometastatic lesions are usually asymptomatic. The MDT team will consider radiotherapy intervention for patients with the following conditions: 1) Stabilized disease following EGFR-TKI treatment: Patients had achieved disease control (either stable disease or partial response on TKIs for at least 6–8 weeks. 2) Residual lesions identifiable on imaging: Despite systemic disease control, imaging revealed residual oligometastatic lesions that were potentially aggressive, persistent, or located at clinically relevant sites. Radiotherapy was added in accordance with current ASTRO/ESTRO guidelines, which recommend the addition of local consolidative therapy (LCT) after initial systemic control in synchronous oligometastatic NSCLC. LCT at this stage aims to reduce tumor burden, eliminate residual foci, and potentially improve PFS by delaying systemic failure<sup><a href="#CR5" class="usa-link" aria-describedby="CR5">5</a></sup>. In this group, radiotherapy was applied to selected oligometastatic lesions rather than all visible lesions.</p>
<p id="Par53">Patients in the post-progression group received radiotherapy after developing oligoprogressive disease while on EGFR-TKI therapy. The decision to proceed with local treatment in this setting was based on the following MDT-assessed criteria: (1) Lesion accessibility and technical feasibility: Only lesions amenable to safe and effective delivery of radiation, based on anatomical location and dosimetric constraints, were considered for treatment. (2) Symptom control: Radiotherapy was prioritized in patients with symptomatic lesions, including those causing pain, cough, hemoptysis, or neurological symptoms, even in the absence of radiographic progression. (3) Oligometastatic disease burden: Patients with limited number (≤ 5) of metastatic lesions and controlled primary tumor were considered eligible for local therapy, in accordance with the definition of oligometastatic disease. All RT decisions were finalized only after MDT consensus, balancing the potential clinical benefit against risks and patient-specific factors.</p>
<p id="Par54">Primary tumors were treated with either hypofractionated radiotherapy (50–60 Gy in 3–8 fractions) or conventionally fractionated radiotherapy (56–66 Gy in 28–33 fractions). Bone metastases were treated with conventional fractionated radiation therapy (30 Gy/10 F or 40–50 Gy/20–25 F depends on radiotherapy site), and brain metastases were treated with conventional fractionated radiation therapy (45–50 Gy/10F).</p></section><section id="Sec15"><h3 class="pmc_sec_title">Follow-up and treatment response assessment</h3>
<p id="Par55">Follow-up time was calculated as the interval from the initiation of first-line EGFR-TKI therapy to the date of radiologically confirmed disease progression, as defined by RECIST version 1.1. All patients in the study experienced progression, and no censoring was applied. Patients were evaluated every 3 months until disease progression. Routine surveillance imaging included chest and abdominal CT scans, as well as brain MRI. Bone scans were performed when bone metastasis was suspected, and PET scans were conducted when systemic progression was suspected. Treatment response, local relapse, and distant metastasis were recorded.</p>
<p id="Par56">The primary endpoint of this study was the duration of first-line EGFR-TKI therapy, defined as the time from the initiation of TKI therapy until the need for a change in treatment due to disease progression; The secondary endpoints were progression-free survival (PFS1), defined as the time from the initiation of TKI therapy to the first disease progression; progression-free survival (PFS2), defined as the time from the first disease progression to subsequent progression; PFS2 was only calculated for patients in the post-progression RT group, as it was defined as the time from first disease progression to second progression or death. Patients in the upfront consolidative RT group had not experienced their first progression at the time of radiotherapy and were therefore not eligible for PFS2 analysis; and radiotherapy progression-free survival (RT-PFS), defined as the time from the initiation of radiotherapy to disease progression; severe treatment-related pneumonitis (TRP), defined as an inflammatory condition of the lungs resulting from cancer therapies such as thoracic radiation therapy, targeted therapies (e.g., EGFR tyrosine kinase inhibitors), or immune checkpoint inhibitors. It is characterized by inflammation of lung tissue, which can lead to symptoms like cough, shortness of breath, and fever.</p></section><section id="Sec16"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par57">Statistical analyses were performed using SPSS 19.0 software (IBM). Descriptive statistics were used to summarize the baseline characteristics of patients. Categorical variables were compared using the Chi-square test, and continuous variables were expressed as mean ± standard deviation or median with interquartile range, depending on the data distribution.</p>
<p id="Par58">Survival analysis was conducted using Kaplan-Meier curves and compared using the log-rank test. For univariate analysis, Cox proportional hazards models were applied to evaluate the association between baseline characteristics and survival outcomes. Variables with a P value &lt; 0.10 (two-sided) in univariate analysis were included in the multivariate Cox proportional hazards model, using a forward selection procedure. In multivariate analysis, P values &lt; 0.05(two-sided) were considered statistically significant.</p>
<p id="Par59">A post hoc power analysis was performed to evaluate whether the study had adequate power to detect the observed difference in TKI duration between the two groups, using a two-sided significance level of 0.05.</p></section></section><section id="Sec17"><h2 class="pmc_sec_title">Supplementary Information</h2>
<p>Below is the link to the electronic supplementary material.</p>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12368105/bin/41598_2025_15056_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (6.6MB, docx) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Not applicable.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>NSCLC</dt>
<dd><p id="Par5">Non-small cell lung cancer</p></dd>
<dt>EGFR</dt>
<dd><p id="Par6">Epidermal growth factor receptor</p></dd>
<dt>TKI</dt>
<dd><p id="Par7">Tyrosine kinase inhibitor</p></dd>
<dt>PFS</dt>
<dd><p id="Par8">Progression-free survival</p></dd>
<dt>RT-PFS</dt>
<dd><p id="Par9">Radiotherapy progression-free survival</p></dd>
<dt>ECOG PS</dt>
<dd><p id="Par10">Eastern Cooperative Oncology Group performance status</p></dd>
<dt>SBRT</dt>
<dd><p id="Par11">Stereotactic body radiotherapy</p></dd>
<dt>TRAEs</dt>
<dd><p id="Par12">Treatment-related adverse events</p></dd>
<dt>ASTRO</dt>
<dd><p id="Par13">American Society for Radiation Oncology</p></dd>
<dt>ESTRO</dt>
<dd><p id="Par14">European Society for Radiotherapy and Oncology</p></dd>
<dt>HR</dt>
<dd><p id="Par15">Hazard ratio</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>H-JW and MZ established the study design. B-YZ and H-JW provided study materials and patients. MZ was responsible for the collection and assembly of data. MZ and QW performed data analysis and interpretation. All authors contributed to the manuscript writing, with final approval of the manuscript provided by all authors.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was supported by the HUI LAN Public Welfare.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The datasets generated and/or analyzed during the current study contain patient-sensitive information and are not publicly available due to confidentiality and ethical restrictions. However, de-identified data may be available from the corresponding author upon reasonable request and with approval from the institutional ethics committee.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par60">The authors declare no competing interests.</p></section><section id="FPar2"><h3 class="pmc_sec_title"><strong>Consent for publication</strong></h3>
<p id="Par61">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Ethics declarations</h3>
<p id="Par62">This study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University, China (Reference No. QYFYWZLL29747). All experiments involving human participants were conducted in accordance with the Declaration of Helsinki and institutional guidelines and regulations. Given the retrospective nature of this study, the requirement for informed consent was waived by the Ethics Committee of the Affiliated Hospital of Qingdao University.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Bi-Yuan Zhang, Email: zhangbiyuan@qdu.edu.cn.</p>
<p>Hai-Ji Wang, Email: wanghaiji@qdu.edu.cn.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Meza, R. et al. Lung cancer incidence trends by gender, race and histology in the united states, 1973–2010. <em>PLoS One</em>. <strong>10</strong> (3), e0121323 (2015).
</cite> [<a href="https://doi.org/10.1371/journal.pone.0121323" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4379166/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25822850/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Meza,%20R.%20et%20al.%20Lung%20cancer%20incidence%20trends%20by%20gender,%20race%20and%20histology%20in%20the%20united%20states,%201973%E2%80%932010.%20PLoS%20One.%2010%20(3),%20e0121323%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Wu, Y. L. et al. Alectinib in resected ALK-Positive Non-Small-Cell lung cancer. <em>N Engl. J. Med.</em><strong>390</strong> (14), 1265–1276 (2024).
</cite> [<a href="https://doi.org/10.1056/NEJMoa2310532" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38598794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wu,%20Y.%20L.%20et%20al.%20Alectinib%20in%20resected%20ALK-Positive%20Non-Small-Cell%20lung%20cancer.%20N%20Engl.%20J.%20Med.390%20(14),%201265%E2%80%931276%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Rotow, J. &amp; Bivona, T. G. Understanding and targeting resistance mechanisms in NSCLC. <em>Nat. Rev. Cancer</em>. <strong>17</strong> (11), 637–658 (2017).
</cite> [<a href="https://doi.org/10.1038/nrc.2017.84" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29068003/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rotow,%20J.%20&amp;%20Bivona,%20T.%20G.%20Understanding%20and%20targeting%20resistance%20mechanisms%20in%20NSCLC.%20Nat.%20Rev.%20Cancer.%2017%20(11),%20637%E2%80%93658%20(2017)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Weichselbaum, R. R. &amp; Hellman, S. Oligometastases revisited. <em>Nat. Rev. Clin. Oncol.</em><strong>8</strong> (6), 378–382 (2011).
</cite> [<a href="https://doi.org/10.1038/nrclinonc.2011.44" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21423255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Weichselbaum,%20R.%20R.%20&amp;%20Hellman,%20S.%20Oligometastases%20revisited.%20Nat.%20Rev.%20Clin.%20Oncol.8%20(6),%20378%E2%80%93382%20(2011)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Iyengar, P. et al. Treatment of oligometastatic Non-Small cell lung cancer: an ASTRO/ESTRO clinical practice guideline. <em>Pract. Radiat. Oncol.</em><strong>13</strong> (5), 393–412 (2023).
</cite> [<a href="https://doi.org/10.1016/j.prro.2023.04.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37294262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Iyengar,%20P.%20et%20al.%20Treatment%20of%20oligometastatic%20Non-Small%20cell%20lung%20cancer:%20an%20ASTRO/ESTRO%20clinical%20practice%20guideline.%20Pract.%20Radiat.%20Oncol.13%20(5),%20393%E2%80%93412%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Gan, G. N. et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving Crizotinib. <em>Int. J. Radiat. Oncol. Biol. Phys.</em><strong>88</strong> (4), 892–898 (2014).
</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2013.11.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4160890/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24462383/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gan,%20G.%20N.%20et%20al.%20Stereotactic%20radiation%20therapy%20can%20safely%20and%20durably%20control%20sites%20of%20extra-central%20nervous%20system%20oligoprogressive%20disease%20in%20anaplastic%20lymphoma%20kinase-positive%20lung%20cancer%20patients%20receiving%20Crizotinib.%20Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.88%20(4),%20892%E2%80%93898%20(2014)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Wang, X. S. et al. Randomized trial of First-Line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-Mutated Non-Small cell lung cancer. <em>J. Natl. Cancer Inst.</em><strong>115</strong> (6), 742–748 (2023).
</cite> [<a href="https://doi.org/10.1093/jnci/djac015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10248839/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35094066/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang,%20X.%20S.%20et%20al.%20Randomized%20trial%20of%20First-Line%20tyrosine%20kinase%20inhibitor%20with%20or%20without%20radiotherapy%20for%20synchronous%20oligometastatic%20EGFR-Mutated%20Non-Small%20cell%20lung%20cancer.%20J.%20Natl.%20Cancer%20Inst.115%20(6),%20742%E2%80%93748%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Weickhardt, A. J. et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. <em>J. Thorac. Oncol.</em><strong>7</strong> (12), 1807–1814 (2012).
</cite> [<a href="https://doi.org/10.1097/JTO.0b013e3182745948" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3506112/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23154552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Weickhardt,%20A.%20J.%20et%20al.%20Local%20ablative%20therapy%20of%20oligoprogressive%20disease%20prolongs%20disease%20control%20by%20tyrosine%20kinase%20inhibitors%20in%20oncogene-addicted%20non-small-cell%20lung%20cancer.%20J.%20Thorac.%20Oncol.7%20(12),%201807%E2%80%931814%20(2012)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Rossi, S. et al. Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <em>Future Oncol.</em><strong>15</strong> (33), 3775–3782 (2019).
</cite> [<a href="https://doi.org/10.2217/fon-2019-0349" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31709807/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rossi,%20S.%20et%20al.%20Survival%20outcome%20of%20tyrosine%20kinase%20inhibitors%20beyond%20progression%20in%20association%20to%20radiotherapy%20in%20oligoprogressive%20EGFR-mutant%20non-small-cell%20lung%20cancer.%20Future%20Oncol.15%20(33),%203775%E2%80%933782%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Xu, Q. et al. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with First-Line EGFR-TKIs. <em>J. Thorac. Oncol.</em><strong>13</strong> (9), 1383–1392 (2018).
</cite> [<a href="https://doi.org/10.1016/j.jtho.2018.05.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29852232/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu,%20Q.%20et%20al.%20Consolidative%20local%20ablative%20therapy%20improves%20the%20survival%20of%20patients%20with%20synchronous%20oligometastatic%20NSCLC%20harboring%20EGFR%20activating%20mutation%20treated%20with%20First-Line%20EGFR-TKIs.%20J.%20Thorac.%20Oncol.13%20(9),%201383%E2%80%931392%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Al-Halabi, H. et al. Pattern of failure analysis in metastatic EGFR-Mutant lung cancer treated with tyrosine kinase inhibitors to identify candidates for consolidation stereotactic body radiation therapy. <em>J. Thorac. Oncol.</em><strong>10</strong> (11), 1601–1607 (2015).
</cite> [<a href="https://doi.org/10.1097/JTO.0000000000000648" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26313684/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Al-Halabi,%20H.%20et%20al.%20Pattern%20of%20failure%20analysis%20in%20metastatic%20EGFR-Mutant%20lung%20cancer%20treated%20with%20tyrosine%20kinase%20inhibitors%20to%20identify%20candidates%20for%20consolidation%20stereotactic%20body%20radiation%20therapy.%20J.%20Thorac.%20Oncol.10%20(11),%201601%E2%80%931607%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Yoshida, T. et al. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation. <em>Lung Cancer</em>. <strong>90</strong> (3), 477–483 (2015).
</cite> [<a href="https://doi.org/10.1016/j.lungcan.2015.09.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26604031/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yoshida,%20T.%20et%20al.%20RECIST%20progression%20patterns%20during%20EGFR%20tyrosine%20kinase%20inhibitor%20treatment%20of%20advanced%20non-small%20cell%20lung%20cancer%20patients%20harboring%20an%20EGFR%20mutation.%20Lung%20Cancer.%2090%20(3),%20477%E2%80%93483%20(2015)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Li, X. Y. et al. Analysis of progression patterns and failure sites of patients with metastatic lung adenocarcinoma with EGFR mutations receiving First-line treatment of tyrosine kinase inhibitors. <em>Clin. Lung Cancer</em>. <strong>21</strong> (6), 534–544 (2020).
</cite> [<a href="https://doi.org/10.1016/j.cllc.2020.04.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32505632/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li,%20X.%20Y.%20et%20al.%20Analysis%20of%20progression%20patterns%20and%20failure%20sites%20of%20patients%20with%20metastatic%20lung%20adenocarcinoma%20with%20EGFR%20mutations%20receiving%20First-line%20treatment%20of%20tyrosine%20kinase%20inhibitors.%20Clin.%20Lung%20Cancer.%2021%20(6),%20534%E2%80%93544%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Miyawaki, T. et al. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. <em>BMC Cancer</em>. <strong>21</strong> (1), 1247 (2021).
</cite> [<a href="https://doi.org/10.1186/s12885-021-08983-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8605535/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34798865/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Miyawaki,%20T.%20et%20al.%20Association%20between%20oligo-residual%20disease%20and%20patterns%20of%20failure%20during%20EGFR-TKI%20treatment%20in%20EGFR-mutated%20non-small%20cell%20lung%20cancer:%20a%20retrospective%20study.%20BMC%20Cancer.%2021%20(1),%201247%20(2021)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Conibear, J. et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. <em>BMJ Open.</em><strong>8</strong> (4), e020690 (2018).
</cite> [<a href="https://doi.org/10.1136/bmjopen-2017-020690" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5905762/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29666135/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Conibear,%20J.%20et%20al.%20Study%20protocol%20for%20the%20SARON%20trial:%20a%20multicentre,%20randomised%20controlled%20phase%20III%20trial%20comparing%20the%20addition%20of%20stereotactic%20ablative%20radiotherapy%20and%20radical%20radiotherapy%20with%20standard%20chemotherapy%20alone%20for%20oligometastatic%20non-small%20cell%20lung%20cancer.%20BMJ%20Open.8%20(4),%20e020690%20(2018)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Peng, P. et al. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study. <em>Radiother Oncol.</em><strong>184</strong>, 109681 (2023).
</cite> [<a href="https://doi.org/10.1016/j.radonc.2023.109681" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37105304/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Peng,%20P.%20et%20al.%20EGFR-TKIs%20plus%20stereotactic%20body%20radiation%20therapy%20(SBRT)%20for%20stage%20IV%20Non-small%20cell%20lung%20cancer%20(NSCLC):%20A%20prospective,%20multicenter,%20randomized,%20controlled%20phase%20II%20study.%20Radiother%20Oncol.184,%20109681%20(2023)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Illini, O. et al. Multidisciplinary treatment of advanced or metastatic ALK-positive non-small cell lung cancer: Real-world data on brigatinib combined with local therapy. <em>Med. (Baltim).</em><strong>104</strong> (17), e42297 (2025).</cite> [<a href="https://doi.org/10.1097/MD.0000000000042297" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12040005/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40295241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Illini,%20O.%20et%20al.%20Multidisciplinary%20treatment%20of%20advanced%20or%20metastatic%20ALK-positive%20non-small%20cell%20lung%20cancer:%20Real-world%20data%20on%20brigatinib%20combined%20with%20local%20therapy.%20Med.%20(Baltim).104%20(17),%20e42297%20(2025)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Elamin, Y. et al. OA22.04 BRIGHTSTAR local consolidative therapy with brigatinib in tyrosine kinase Inhibitor-Naïve ALK-Rearranged metastatic NSCLC. <em>J. Thorac. Oncol.</em><strong>18</strong>(11), S96 (2023).</cite>
</li>
<li id="CR19">
<span class="label">19.</span><cite>Lang, P., Gomez, D. R. &amp; Palma, D. A. Local ablative therapies in oligometastatic NSCLC: new data and new directions. <em>Semin Respir Crit. Care Med.</em><strong>41</strong> (3), 369–376 (2020).
</cite> [<a href="https://doi.org/10.1055/s-0039-3400290" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32450591/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lang,%20P.,%20Gomez,%20D.%20R.%20&amp;%20Palma,%20D.%20A.%20Local%20ablative%20therapies%20in%20oligometastatic%20NSCLC:%20new%20data%20and%20new%20directions.%20Semin%20Respir%20Crit.%20Care%20Med.41%20(3),%20369%E2%80%93376%20(2020)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Chen, Y. H., Ho, U. C. &amp; Kuo, L. T. Oligometastatic disease in Non-Small-Cell lung cancer: an update. <em>Cancers (Basel)</em><strong>14</strong>(5), 1350 (2022).</cite> [<a href="https://doi.org/10.3390/cancers14051350" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8909159/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35267658/" class="usa-link">PubMed</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Sun, H. et al. Thoracic radiotherapy improves the survival in patients with EGFR-Mutated Oligo-Organ metastatic Non-Small cell lung cancer treated with epidermal growth factor Receptor-Tyrosine kinase inhibitors: A multicenter, randomized, controlled, phase III trial. <em>J. Clin. Oncol.</em><strong>43</strong> (4), 412–421 (2025).
</cite> [<a href="https://doi.org/10.1200/JCO.23.02075" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39374473/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun,%20H.%20et%20al.%20Thoracic%20radiotherapy%20improves%20the%20survival%20in%20patients%20with%20EGFR-Mutated%20Oligo-Organ%20metastatic%20Non-Small%20cell%20lung%20cancer%20treated%20with%20epidermal%20growth%20factor%20Receptor-Tyrosine%20kinase%20inhibitors:%20A%20multicenter,%20randomized,%20controlled,%20phase%20III%20trial.%20J.%20Clin.%20Oncol.43%20(4),%20412%E2%80%93421%20(2025)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Li, X. et al. Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis. <em>Future Oncol.</em><strong>18</strong> (27), 3055–3065 (2022).
</cite> [<a href="https://doi.org/10.2217/fon-2022-0491" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35947522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li,%20X.%20et%20al.%20Efficacy%20and%20safety%20of%20EGFR%20inhibitors%20and%20radiotherapy%20in%20locally%20advanced%20non-small-cell%20lung%20cancer:%20a%20meta-analysis.%20Future%20Oncol.18%20(27),%203055%E2%80%933065%20(2022)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Meng, Y. et al. Treatment-Related pneumonitis of EGFR tyrosine kinase inhibitors plus thoracic radiation therapy in patients with Non-Small cell lung cancer: A systematic review and Meta-Analysis. <em>Int. J. Radiat. Oncol. Biol. Phys.</em><strong>118</strong> (2), 415–426 (2024).
</cite> [<a href="https://doi.org/10.1016/j.ijrobp.2023.09.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37716460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Meng,%20Y.%20et%20al.%20Treatment-Related%20pneumonitis%20of%20EGFR%20tyrosine%20kinase%20inhibitors%20plus%20thoracic%20radiation%20therapy%20in%20patients%20with%20Non-Small%20cell%20lung%20cancer:%20A%20systematic%20review%20and%20Meta-Analysis.%20Int.%20J.%20Radiat.%20Oncol.%20Biol.%20Phys.118%20(2),%20415%E2%80%93426%20(2024)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Dingemans, A. C. et al. Definition of synchronous oligometastatic Non-Small cell lung Cancer-A consensus report. <em>J. Thorac. Oncol.</em><strong>14</strong> (12), 2109–2119 (2019).
</cite> [<a href="https://doi.org/10.1016/j.jtho.2019.07.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31398540/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dingemans,%20A.%20C.%20et%20al.%20Definition%20of%20synchronous%20oligometastatic%20Non-Small%20cell%20lung%20Cancer-A%20consensus%20report.%20J.%20Thorac.%20Oncol.14%20(12),%202109%E2%80%932119%20(2019)." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12368105/bin/41598_2025_15056_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Supplementary Material 1</a><sup> (6.6MB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The datasets generated and/or analyzed during the current study contain patient-sensitive information and are not publicly available due to confidentiality and ethical restrictions. However, de-identified data may be available from the corresponding author upon reasonable request and with approval from the institutional ethics committee.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Scientific Reports are provided here courtesy of <strong>Nature Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1038/s41598-025-15056-y"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/41598_2025_Article_15056.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12368105/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12368105/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12368105%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368105/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12368105/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12368105/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40836051/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12368105/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40836051/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12368105/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12368105/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="Utf8EjCfLSvtXfeGAf2jGI9xh5MAlsb1Vv1l2drbULRaNJ4LiGOyTxVOs2IrBJk9">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
